Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
154 0
SM ISO690:2012
ERKUNER, Omer; VATAMAN, Eleonora; GROSU, Aurel. Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). In: American Journal of Cardiology. 2018, nr. 4(122), pp. 578-583. ISSN 0002-9149.
EXPORT metadate:
Google Scholar
Crossref
CERIF
BibTeX
DataCite
Dublin Core
American Journal of Cardiology
Numărul 4(122) / 2018 / ISSN 0002-9149

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey)


DOI: 10.1016/j.amjcard.2018.04.053
Pag. 578-583

Erkuner Omer1, Vataman Eleonora2, Grosu Aurel3
 
1 Maastricht University,
2 Academy of Sciences of Moldova,
3 Institute of Cardiology
 
Disponibil în IBN: 24 iunie 2019


Rezumat

Hypertension is a risk factor for both progression of atrial fibrillation (AF) and development of AF-related complications, that is major adverse cardiac and cerebrovascular events (MACCE). It is unknown whether left ventricular hypertrophy (LVH) as a consequence of hypertension is also a risk factor for both these end points. We aimed to assess this in low-risk AF patients, also assessing gender-related differences. We included 799 patients from the Euro Heart Survey with nonvalvular AF and a baseline echocardiogram. Patients with and without hypertension were included. End points after 1 year were occurrence of AF progression, that is paroxysmal AF becoming persistent and/or permanent AF, and MACCE. Echocardiographic LVH was present in 33% of 379 hypertensive patients. AF progression after 1 year occurred in 10.2% of 373 patients with rhythm follow-up. In hypertensive patients with LVH, AF progression occurred more frequently as compared with hypertensive patients without LVH (23.3% vs 8.8%, p = 0.011). In hypertensive AF patients, LVH was the most important multivariably adjusted determinant of AF progression on multivariable logistic regression (odds ratio 4.84, 95% confidence interval 1.70 to 13.78, p = 0.003). This effect was only seen in male patients (27.5% vs 5.8%, p = 0.002), while in female hypertensive patients, no differences were found in AF progression rates regarding the presence or absence of LVH (15.2% vs 15.0%, p = 0.999). No differences were seen in MACCE for hypertensive patients with and without LVH. In conclusion, in men with hypertension, LVH is associated with AF progression. This association seems to be absent in hypertensive women.

Cuvinte-cheie
angiotensin receptor antagonist, antiarrhythmic agent, antivitamin K, beta adrenergic receptor blocking agent, calcium channel blocking agent, dihydropyridine derivative, dipeptidyl carboxypeptidase inhibitor, diuretic agent